Platform

Our platform technology is geared towards the development of assets with short timelines and cost-effective paths to value creation.

Description

ExpreS2ion Biotechnologies has developed the ExpreS2 platform, a proprietary protein expression system based on engineered Drosophila Schneider-2 (S2) cells. This innovative platform supports recombinant protein production for the biopharmaceutical industry and academia.

With over a decade of success, the ExpreS2 platform has a remarkable track record of expressing more than 500 proteins with a success rate above 90%. It offers rapid delivery within 3-6 months and ensures high batch-to-batch consistency.

Application

ExpreS2 combines the benefits of using insect and mammalian cells, optimizing effort and product quality. Our patented expression vectors enable higher yields, and since 2019, our GlycoX-S2™ cell lines have enabled enhanced immunogenicity and pharmacokinetics.

Proofs-of-concept

The ExpreS2 platform technology advantages

1) Enables development of novel vaccines

Advantages to other vaccine types

1. Safety
Inherently safe, as they cannot replicate and cause infection.

2. Immunogenicity
Induce a strong immune response due to their similarity to real viruses when combined with a virus-like particle.

3. Versatility
ExpreS2 is the basis for vaccines against a wide variety of diseases, with and without delivery vehicles.

2) Enables production of hard-to-express proteins

Advantages to other protein-production methods

1. Speed in production 2. Higher yields 3. Homogeneous manufacturing batches 4. Thermal stability 5. Functional modification options

Illustration

Vaccine using ExpreS2™ produced antigens and virus-like particle (VLP)